Advanced Materials Technology led the revolution in Fused-Core® particle technology with the development of the first commercially available sub-3 µm superficially porous particle (SPP) with the original HALO® 2.7 µm particle. This manufacturing expertise has carried forward into AMT being the wide pore particle leader. This innovative culture has been transferred to developing novel materials for the biotherapeutic market. HALO® particles are ready to solve the characterization challenges of these complex separations.
Today, researchers are keenly interested in both fast and high resolution separations of numerous biomolecules to support the development of novel therapeutic proteins and peptides in pharmaceutical drug development, advance academic understanding in modern University laboratories, characterize protein post-translation modifications, and to fully assess subtle differences in biosimilars and other products of bioengineering and manufacturing. HALO® BioClass columns have been developed to simplify and promote a more comprehensive understanding - faster.
- Intact proteins, monoclonal antibodies (mAbs), biosimilars, and other large biomolecules such as pegylated proteins, antibody drug conjugates (ADCs)
- Peptide mapping (analysis of enzyme digests) for characterization and monitoring of synthetic protein drugs
- Analysis of therapeutic peptides and peptide biomarkers (protein surrogates)
- High resolution separations of complex mixtures of glycans released from N- and O-linked glycoproteins